seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Company profile
Ticker
MCRB
Exchange
Website
CEO
Eric Shaff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Seres Health, Inc.
SEC CIK
Corporate docs
Subsidiaries
Seres Therapeutics Securities Corporation • Seres Therapeutics UK Limited • Seres Therapeutics Netherlands B.V. ...
MCRB stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Apr 24
DEF 14A
Definitive proxy
5 Mar 24
S-8
Registration of securities for employees
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
5 Mar 24
8-K
Seres Therapeutics Announces the Appointment of Marella Thorell As Chief Financial Officer and the Retirement of David Arkowitz
26 Feb 24
PRE 14A
Preliminary proxy
23 Feb 24
8-K
Other Events
30 Jan 24
8-K
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
10 Jan 24
Transcripts
MCRB
Earnings call transcript
2023 Q4
5 Mar 24
MCRB
Earnings call transcript
2023 Q3
2 Nov 23
MCRB
Earnings call transcript
2023 Q2
8 Aug 23
MCRB
Earnings call transcript
2023 Q1
9 May 23
MCRB
Earnings call transcript
2022 Q4
7 Mar 23
MCRB
Earnings call transcript
2022 Q3
2 Nov 22
MCRB
Earnings call transcript
2022 Q2
3 Aug 22
MCRB
Earnings call transcript
2022 Q1
4 May 22
MCRB
Earnings call transcript
2021 Q4
1 Mar 22
MCRB
Earnings call transcript
2021 Q3
10 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 178.10 mm | 178.10 mm | 178.10 mm | 178.10 mm | 178.10 mm | 178.10 mm |
Cash burn (monthly) | 19.87 mm | 2.96 mm | 15.80 mm | 11.40 mm | 19.75 mm | 10.23 mm |
Cash used (since last report) | 135.03 mm | 20.10 mm | 107.40 mm | 77.45 mm | 134.23 mm | 69.51 mm |
Cash remaining | 43.07 mm | 158.00 mm | 70.69 mm | 100.64 mm | 43.87 mm | 108.58 mm |
Runway (months of cash) | 2.2 | 53.4 | 4.5 | 8.8 | 2.2 | 10.6 |
Institutional ownership, Q3 2023
82.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 136 |
Opened positions | 21 |
Closed positions | 25 |
Increased positions | 54 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 251.20 bn |
Total shares | 123.78 mm |
Total puts | 354.90 k |
Total calls | 502.60 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Flagship Pioneering | 23.12 mm | $55.02 bn |
FMR | 19.23 mm | $45.77 bn |
STT State Street | 9.54 mm | $22.70 bn |
FHI Federated Hermes Inc - Ordinary Shares | 8.98 mm | $21.38 bn |
Flagship VentureLabs IV | 8.79 mm | $33.66 mm |
BLK Blackrock | 7.92 mm | $18.85 bn |
Nestle Health Science US | 7.59 mm | $26.58 mm |
Vanguard | 5.48 mm | $13.03 bn |
JHG Janus Henderson | 2.81 mm | $6.70 bn |
Point72 Asset Management | 2.75 mm | $6.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Apr 24 | Graves Kurt | Stock Option Common Stock | Grant | Acquire A | No | No | 0.76 | 60,000 | 45.60 k | 60,000 |
4 Apr 24 | Kender Richard N | Stock Option Common Stock | Grant | Acquire A | No | No | 0.76 | 60,000 | 45.60 k | 60,000 |
4 Apr 24 | Biondi Paul | Stock Option Common Stock | Grant | Acquire A | No | No | 0.76 | 60,000 | 45.60 k | 60,000 |
4 Apr 24 | Fraser Claire | Stock Option (right to buy Common Stock | Grant | Acquire A | No | No | 0.76 | 60,000 | 45.60 k | 60,000 |
4 Apr 24 | Willard H Dere | Stock Option Common Stock | Grant | Acquire A | No | No | 0.76 | 60,000 | 45.60 k | 60,000 |
News
Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $5
6 Mar 24
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
6 Mar 24
Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8
6 Mar 24
Seres Therapeutics FY GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $126.33M Beat $126.07M Estimate
5 Mar 24
Earnings Scheduled For March 5, 2024
5 Mar 24
Press releases
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
9 Apr 24
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
19 Mar 24
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
28 Feb 24
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
27 Feb 24